NCT06909565ClinicalTrials.gov
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
In brief
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on…
Phase 46,000 participants sought153 sites1 country
Categories
Registered in 1 registry
- ClinicalTrials.govNCT06909565Open this record at ClinicalTrials.govSynced 2 days ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-04-03; recorded start 2025-07-23
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 475 other studies in this databaseCounted from the lead sponsor named in the record (Duke University)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 4 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 115 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 6,000 participants (target), run at 153 sites.
How this score is built
- Enrolment36/40
6,000 participants (target)
- Site count23/25
115 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 53 months
- Sponsor scale10/10
Duke University has led 456 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Conditions
- Percutaneous Coronary Intervention
- Peripheral Endovascular Intervention
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 4 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | PREVENTION |
| Masking | QUADRUPLE (4) |
| Enrolment | 6,000 participants sought |
Sponsor and collaborators
- Duke University Sponsor
- Novartis Pharmaceuticals Collaborators
- Colorado Prevention Center Collaborators
- Mount Sinai Hospital, New York Collaborators
Arms and interventions
- Inclisiran SodiumACTIVE_COMPARATOR
Inclisiran sodium 300 mg subcutaneous injection
- PlaceboPLACEBO_COMPARATOR
Normal saline 1.5 ml subcutaneous injection
Interventions
- Drug Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
- Drug Normal Saline (Placebo)
Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
Outcome measures
Primary outcome
Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularization
MACEs include CHD death, non-fatal MI, ischemic stroke, ALI, major (above the ankle) amputation of vascular etiology, clinically driven coronary and limb revascularization.
Time frame From randomization to first occurrence of MACE (up to approximately 4 years)
Primary outcome
Total number of major adverse limb events (MALE) after endovascular revascularization
MALEs consist of ALI, major amputation of vascular etiology, clinically driven lower extremity peripheral revascularization.
Time frame From randomization to first occurrence of MALE (up to approximately 4 years)
Secondary outcome
Number of participants with cardiovascular (CV) death
Time frame From randomization to CV death (up to approximately 4 years)
Secondary outcome
Number of participants with all cause death
Time frame From randomization to all cause death (up to approximately 4 years)
Secondary outcome
Number of participants with venous thromboembolic events (VTE)
Time frame From randomization to first VTE (up to approximately 4 years)
Dates
| Start date | July 23, 2025 (actual) |
|---|---|
| Primary completion | October 1, 2029 (estimated) |
| Completion | December 1, 2029 (estimated) |
| First posted | April 3, 2025 (actual) |
| Last updated | November 16, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | July 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
149 sites are recruiting
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Capital Cardiology Associates | Albany | New York | Recruiting |
| Presbyterian Heart Group | Albuquerque | New Mexico | Recruiting |
| Advanced Cardiovascular LLC | Alexander City | Alabama | Recruiting |
| Amarillo Heart Clinical Research Institute, Inc. | Amarillo | Texas | Recruiting |
| PharmaTex Research | Amarillo | Texas | Recruiting |
| AnMed Health Medical Center | Anderson | South Carolina | Recruiting |
| Asheville Cardiology Associates Research Department | Asheville | North Carolina | Recruiting |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | Recruiting |
| Austin Heart | Austin | Texas | Recruiting |
| IMS Cardiology | Avondale | Arizona | Recruiting |
| Northern Light Eastern Maine Medical Center | Bangor | Maine | Recruiting |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | Recruiting |
| Pacific Oaks Medical Group | Beverly Hills | California | Recruiting |
| Cardiology, PC | Birmingham | Alabama | Recruiting |
| Grace Research, LLC | Bossier City | Louisiana | Recruiting |
| Bridgeport Hospital | Bridgeport | Connecticut | Recruiting |
| Advanced Heart Care LLC | Bridgewater | New Jersey | Recruiting |
| Trinity Medical WNY, PC | Buffalo | New York | Recruiting |
| Sisters of Charity Hospital | Buffalo | New York | Recruiting |
| Capital Area Research LLC | Camp Hill | Pennsylvania | Recruiting |
| Aultman Hospital | Canton | Ohio | Recruiting |
| Wellspan Chambersburg Hospital | Chambersburg | Pennsylvania | Recruiting |
| Mecklenburg Heart Specialists | Charlotte | North Carolina | Recruiting |
| Novant Health Clinical Research/Heart & Vascular Institute | Charlotte | North Carolina | Recruiting |
| Atrium Health-Sanger Heart and Vascular Institute | Charlotte | North Carolina | Recruiting |
| University of Illinois Chicago | Chicago | Illinois | Recruiting |
| Cardiovascular Institute of San Diego | Chula Vista | California | Recruiting |
| Clearwater Cardiovascular Consultants | Clearwater | Florida | Recruiting |
| BayCare Medical Group | Clearwater | Florida | Recruiting |
| MedStar Southern Maryland Hospital Center | Clinton | Maryland | Recruiting |
| University of Missouri Health Care | Columbia | Missouri | Recruiting |
| John Muir Medical Center - Concord Campus | Concord | California | Recruiting |
| Javara inc. | Conroe | Texas | Withdrawn |
| Pioneer Clinical Studies | Coral Gables | Florida | Recruiting |
| Valley Clinical Trials | Covina | California | Withdrawn |
| Louisiana Heart Center | Covington | Louisiana | Recruiting |
| Nuvance Health- Danbury Hospital | Danbury | Connecticut | Recruiting |
| Cardiology Research Associates | Daytona Beach | Florida | Recruiting |
| Arrow Clinical Trails | Daytona Beach | Florida | Recruiting |
| Essentia Health-SMMC | Duluth | Minnesota | Recruiting |
| Aspirus Saint Luke's Hospital | Duluth | Minnesota | Recruiting |
| Midwest Cardiovascular Research and Education Foundation | Elkhart | Indiana | Recruiting |
| Cardiovascular Associates of the Delaware Valley | Elmer | New Jersey | Recruiting |
| Aurora Denver Cardiology Associates - Englewood | Englewood | Colorado | Recruiting |
| Javara Inc. | Fayetteville | North Carolina | Recruiting |
| Advanced Heart and Vascular Institute Of Hunterdon | Flemington | New Jersey | Recruiting |
| Northeast Georgia Heart Center, PC | Gainesville | Georgia | Recruiting |
| Stern Cardiovascular Center | Germantown | Tennessee | Recruiting |
| Thrive Clinical Research Group | Glendora | California | Recruiting |
| CHI Health Nebraska Heart | Grand Island | Nebraska | Recruiting |
103 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- November 16, 2026
Site added
4 sites added (153 total)
149153
- October 29, 2026
Site added
2 sites added (149 total)
147149
- October 23, 2026
Site added
2 sites added (147 total)
145147
- October 19, 2026
Site added
3 sites added (145 total)
142145
- October 5, 2026
Site added
1 site added (142 total)
141142
- September 28, 2026
Site added
2 sites added (141 total)
139141
- September 22, 2026
Site added
1 site added (139 total)
138139
- September 15, 2026
Site added
2 sites added (138 total)
136138
- August 28, 2026
Site added
3 sites added (136 total)
133136
- August 18, 2026
Site added
8 sites added (133 total)
125133
- August 5, 2026
Site added
10 sites added (125 total)
115125